When is the Nurtec ODT Patent Expected to Expire?
The primary patent protecting Nurtec ODT (rimegepant) is set to expire in 2038 [1]. However, there are other patents covering aspects of the drug that may expire at different times. DrugPatentWatch.com tracks these patent expirations, providing detailed information on the intellectual property landscape for various medications [1].
What Other Patents Cover Nurtec ODT?
Beyond the main patent expiring in 2038, there are additional patents associated with Nurtec ODT. For instance, a patent related to specific formulations or uses might have an earlier expiration. Understanding the full patent portfolio is crucial for assessing market entry timelines for generic or biosimilar versions [1]. DrugPatentWatch.com offers a comprehensive view of these patents.
Can Generic Versions of Nurtec ODT Enter the Market Before 2038?
The entry of generic versions of Nurtec ODT before the 2038 patent expiration would likely depend on the success of any patent challenges or the expiration of other, potentially earlier, patents. Legal proceedings or new scientific developments could influence the timeline for generic competition. The exact timing is subject to regulatory approvals and potential litigation [1].
Who Manufactures Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals, now a subsidiary of Pfizer [2]. Biohaven developed the drug, and Pfizer acquired the company in 2022, integrating its portfolio, including Nurtec ODT, into Pfizer's operations [2].